We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Priority Paper Evaluation

Early intranasal insulin therapy halts progression of neurodegeneration: progress in Alzheimer’s disease therapeutics

    Suzanne M de la Monte

    Pierre Galletti Research Building, Rhode Island Hospital, 55 Claverick Street, Room 419, Providence, RI 02903, USA.

    Search for more papers by this author

    Email the corresponding author at suzanne_delamonte_md@brown.edu

    Published Online:1 Feb 2012https://doi.org/10.2217/ahe.11.89

    Abstract

    Evaluation of: Craft S, Baker LD, Montine TJ et al. Intranasal insulin therapy for Alzheimer’s disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 69(1), 29–38 (2011). Alzheimer’s disease is associated with brain insulin deficiency and insulin resistance, similar to the problems in diabetes. If insulin could be supplied to the brain in the early stages of Alzheimer’s, subsequent neurodegeneration might be prevented. Administering systemic insulin to elderly nondiabetics poses unacceptable risks of inadvertant hypoglycemia. However, intranasal delivery directs the insulin into the brain, avoiding systemic side effects. This pilot study demonstrates both efficacy and safety of using intranasal insulin to treat early Alzheimer’s and mild cognitive impairment (i.e., the precursor to Alzheimer’s). Significant improvements in learning, memory and cognition occurred within a few months, but without intranasal insulin, brain function continued to deteriorate in measurable degrees. Intranasal insulin therapy holds promise for halting progression of Alzheimer’s disease.

    References

    • 1  Craft S, Baker LD, Montine TJ et al. Intranasal insulin therapy for Alzheimer’s disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol.69(1),29–38 (2011).
      MedlineGoogle Scholar
    • 2  de la Monte SM, Neusner A, Chu J, Lawton M. Epidemiological trends strongly suggest exposures as etiologic agents in the pathogenesis of sporadic Alzheimer’s disease, diabetes mellitus, and non-alcoholic steatohepatitis. J. Alzheimers Dis.17(3),519–529 (2009).
      Medline CASGoogle Scholar
    • 3  de la Monte SM. Therapeutic targets of brain insulin resistance in sporadic Alzheimer’s disease. Front. Biosci. (Elite Edition)4,1582–1605 (2012).
      MedlineGoogle Scholar
    • 4  Craft S. Insulin resistance and Alzheimer’s disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer Res.4(2),147–152 (2007).
      Medline CASGoogle Scholar
    • 5  Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine. J. Alzheimers Dis.8(3),247–268 (2005).
      Medline CASGoogle Scholar
    • 6  Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol.490(1–3),115–125 (2004).
      Medline CASGoogle Scholar
    • 7  Hoyer S. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv. Exp. Med. Biol.541,135–152 (2004).
      Medline CASGoogle Scholar
    • 8  Hoyer S, Nitsch R, Oesterreich K. Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J. Neural Transm. Park. Dis. Dement. Sect.3(1),1–14 (1991).
      Medline CASGoogle Scholar
    • 9  de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J. Alzheimers Dis.7(1),45–61 (2005).
      Medline CASGoogle Scholar
    • 10  de la Monte SM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer’s disease. Drugs72(1),1–18 (2011).
      Google Scholar
    • 11  Biswas SC, Buteau J, Greene LA. Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochem. Res.33(9),1845–1851 (2008).
      Medline CASGoogle Scholar
    • 12  Holscher C, Li L. New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer’s disease? Neurobiol. Aging31(9),1495–1502 (2010).
      MedlineGoogle Scholar
    • 13  Perry T, Lahiri DK, Sambamurti K et al. Glucagon-like peptide-1 decreases endogenous amyloid-β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron. J. Neurosci. Res.72(5),603–612 (2003).
      Medline CASGoogle Scholar
    • 14  Holscher C. Incretin analogues that have been developed to treat Type 2 diabetes hold promise as a novel treatment strategy for Alzheimer’s disease. Recent Pat. CNS Drug. Discov.5(2),109–117 (2010).
      Medline CASGoogle Scholar
    • 15  Perry T, Greig NH. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer’s disease. Curr. Alzheimer Res.2(3),377–385 (2005).
      Medline CASGoogle Scholar
    • 16  Liu J, Yin F, Zheng X, Jing J, Hu Y. Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem. Int.51(6–7),361–369 (2007).
      Medline CASGoogle Scholar
    • 17  Liu JH, Yin F, Guo LX, Deng XH, Hu YH. Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta Pharmacol. Sin.30(2),159–165 (2009).
      MedlineGoogle Scholar
    • 18  Heile AM, Wallrapp C, Klinge PM, Samii A, Kassem M, Silverberg G et al. Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury. Neurosci. Lett.463(3),176–181 (2009).
      Medline CASGoogle Scholar
    • 19  Ma YH, Zhang Y, Cao L et al. Effect of neurotrophin-3 genetically modified olfactory ensheathing cells transplantation on spinal cord injury. Cell Transplant.19(2),167–177 (2010).
      MedlineGoogle Scholar
    • 20  Wakabayashi K, Nagai A, Sheikh AM et al. Transplantation of human mesenchymal stem cells promotes functional improvement and increased expression of neurotrophic factors in a rat focal cerebral ischemia model. J. Neurosci. Res.88(5),1017–1025 (2010).
      Medline CASGoogle Scholar